Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study
Journal of the European Academy of Dermatology and Venereology · 2026-10 · 40 (10) · 1702-1712
DOI: 10.1111/jdv.70512 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 08.06.2026. Verfasst von Tristan V M Bruijn und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Fasciitis, Immune Checkpoint Inhibitors, Eosinophilia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune‐related adverse events (cirAEs), including ICI‐induced eosinophilic fasciitis (ICI‐EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse.
Objectives
This study aimed to further characterize the clinical features and outcomes of ICI‐EF.
Methods
This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI‐EF cases from EADV Task Force‐affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow‐up data were extracted from the medical records and databases.
Results
We present 121 ICI‐EF cases from the EADV Task Force ( n = 15), FPVD ( n = 21), VigiBase® ( n = 45) and the literature ( n = 40). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD‐1 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI‐EF onset was 10 months (IQR 6.8–16.3; range < 1–36). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI‐EF symptoms (66%).
Conclusions
ICI‐EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Dermatology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoek, Amsterdam, The Netherlands.
- Department of Clinical Pharmacology, Université Côte d'Azur, University Hospital Centre of Nice, Nice, France.
- Laboratory of Molecular Physio Medicine (LP2M), UMR 7370, CNRS, Université Côte d'Azur, Nice, France.
- Saint Louis Régional Pharmacovigilance Centre, Clinical Investigation Centre (INSERM CIC 1427), Saint-Louis Hospital, Paris, France.
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
ORCID-Profile: Tristan V M Bruijn, Zoe Apalla, Dimitra Koumaki, Frederic Dezoteux, Ander Mayor, Vincent Sibaud, Yannick S Elshot
Zitieren
APA
Bruijn, T. V. M., Gérard, A. O., Labat, M., Apalla, Z., Binsbergen, W. V., Koumaki, D., Rivet, V., Dezoteux, F., Giacchero, D., Ardern-Jones, M. R., Heelan, K., Hirner, J. P., Mayor, A., Labots, M., Starink, M. V., Laken, C. J. V., Sibaud, V., & Elshot, Y. S. (2026). Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study. Journal of the European Academy of Dermatology and Venereology, 40(10), 1702-1712. https://doi.org/10.1111/jdv.70512
Vancouver
Bruijn TVM, Gérard AO, Labat M, Apalla Z, Binsbergen WV, Koumaki D, et al. Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study. Journal of the European Academy of Dermatology and Venereology. 2026;40(10):1702-1712. doi:10.1111/jdv.70512
BibTeX
@article{Bruijn2026,
author = {Bruijn, Tristan V M and Gérard, Alexandre O and Labat, Maëlys and Apalla, Zoe and Binsbergen, Wouter van and Koumaki, Dimitra and Rivet, Valerian and Dezoteux, Frederic and Giacchero, Damien and Ardern-Jones, Michael R and Heelan, Kara and Hirner, Jesse P and Mayor, Ander and Labots, Mariette and Starink, Markus V and Laken, Conny J van der and Sibaud, Vincent and Elshot, Yannick S},
title = {Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {10},
pages = {1702--1712},
doi = {10.1111/jdv.70512}
}
EUVIMED